Sage Journals: Discover world-class research

Abstract

Background:

Cerebrospinal fluid (CSF) immunoglobulin free light chains (FLC) have been suggested as quantitative alternative to oligoclonal bands (OCB) in the diagnosis of multiple sclerosis (MS). However, little is known on their role in predicting clinical and paraclinical disease progression, particularly in early stages.

Objective:

To assess the prognostic value of FLC in OCB-positive patients with clinically isolated syndrome (CIS) suggestive of MS and early MS.

Methods:

We determined FLC kappa (KFLC) and lambda (LFLC) in CSF and serum by nephelometry in 61 patients (CIS (n = 48), relapsing-remitting multiple sclerosis (n = 13)) and 60 non-inflammatory neurological controls. Median clinical follow-up time in CIS was 4.8 years (interquartile range (IQR), 1.5–6.5 years). Patients underwent 3T magnetic resonance imaging (MRI) at baseline and follow-up (median time interval, 2.2 years; IQR, 1.0–3.7 years) to determine T2 lesion load (T2LL) and percent brain volume change (PBVC).

Results:

CSF FLC were significantly increased in CIS/MS compared to controls (all p < 0.001). A lower KFLC/LFLC CSF ratio was associated with CIS-clinically definite multiple sclerosis (CDMS) conversion (hazard ratio (HR) = 2.89; 95% confidence interval (CI) = 1.17–7.14; p < 0.05). No correlations were found for FLC variables with T2LL or PBVC.

Conclusion:

Our study confirms increased intrathecal synthesis of FLC in CIS/MS which supports their diagnostic contribution. The KFLC/LFLC CSF ratio appears to have a prognostic value in CIS beyond OCB.

Keywords

Multiple sclerosis magnetic resonance imaging immunoglobulin kappa chains immunoglobulin lambda chains prognosis cerebrospinal fluid serum

Get full access to this article

View all access options for this article.

References

Polman

Reingold

Banwell

et al . Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 2011; 69(2): 292–302.

Hassan-Smith

Durant

Tsentemeidou

et al . High sensitivity and specificity of elevated cerebrospinal fluid kappa free light chains in suspected multiple sclerosis. J Neuroimmunol 2014; 276(1–2): 175–179.

Presslauer

Milosavljevic

Huebl

et al . Kappa free light chains: Diagnostic and prognostic relevance in MS and CIS. PLoS ONE 2014; 9(2): e89945.

Duranti

Pieri

Centonze

et al . Determination of κFLC and κ index in cerebrospinal fluid: A valid alternative to assess intrathecal immunoglobulin synthesis. J Neuroimmunol 2013; 263(1–2): 116–120.

Presslauer

Milosavljevic

Huebl

et al . Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: A multicenter study. Mult Scler 2015; 22(4): 502–510.

Kaplan

Aizenbud

Golderman

et al . Free light chain monomers in the diagnosis of multiple sclerosis. J Neuroimmunol 2010; 229(1–2): 263–271.

Senel

Tumani

Lauda

et al . Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis. PLoS ONE 2014; 9(4): e88680.

Arneth

Birklein

. High sensitivity of free lambda and free kappa light chains for detection of intrathecal immunoglobulin synthesis in cerebrospinal fluid. Acta Neurol Scand 2009; 119(13): 39–44.

Kuhle

Distanto

Dobson

et al . Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Mult Scler 2015; 21(8): 1013–1024.

10.

Tintoré

Rovira

Río

et al . Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008; 70(13 Pt 2): 1079–1083.

11.

Villar

Espiño

Costa-Frossard

et al . High levels of cerebrospinal fluid free kappa chains predict conversion to multiple sclerosis. Clin Chim Acta 2012; 413(23): 1813–1816.

12.

Desplat-Jégo

Feuillet

Pelletier

et al . Quantification of immunoglobulin free light chains in cerebrospinal fluid by nephelometry. J Clin Immunol 2005; 25(4): 338–345.

13.

Makshakov

Nazarov

Kochetova

et al . Diagnostic and prognostic value of the cerebrospinal fluid concentration of immunoglobulin free light chains in clinically isolated syndrome with conversion to multiple sclerosis. PLoS ONE 2015; 10(11): 1–12.

14.

Mcdonald

Compston

Edan

et al . Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127.

15.

Teunissen

Menge

Altintas

et al . Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler 2013; 19(13): 1802–1809.

16.

Kurtzke

. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1453.

17.

Khalil

Enzinger

Langkammer

et al . Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Mult Scler 2009; 15(9): 1048–1054.

18.

Teunissen

Petzold

Bennett

et al . A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009; 73: 1914–1922.

19.

Felgenhauer

Schliep

Rapic

. Evaluation of the blood-CSF barrier by protein gradients and the humoral immune response within the central nervous system. J Neurol Sci 1976; 30: 113–128.

20.

Link

Tibbling

. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest 1977; 37(5): 397–401.

21.

Andersson

Alvarez-Cermeño

Bernardi

et al . Cerebrospinal fluid in the diagnosis of multiple sclerosis: A consensus report. J Neurol Neurosurg Psychiatry 1994; 57: 897–902.

22.

Khalil

Langkammer

Gattringer

et al . Dynamics of brain iron levels in multiple sclerosis. Neurology 2015; 84: 2396–2402.

23.

Khalil

Langkammer

Ropele

et al . Determinants of brain iron in multiple sclerosis: A quantitative 3T MRI study. Neurology 2011; 77(18): 1691–1697.

24.

Plummer

. DispImage: A display and analysis tool for medical images. Rev Neuroradiol 1992; 5(4): 489–495.

25.

Smith

Jenkinson

Woolrich

et al . Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004; 23(Suppl. 1): S208–S219.

26.

Rudick

Cookfair

Simonian

et al . Cerebrospinal fluid abnormalities in a phase III trial of Avonex® IFNβ-1a for relapsing multiple sclerosis. J Neuroimmunol 1999; 93: 8–14.

27.

Pröbstel

A-K

Sanderson

Derfuss

. B cells and autoantibodies in multiple sclerosis. Int J Mol Sci 2015; 16(7): 16576–16592.

28.

Freedman

Thompson

Deisenhammer

et al . Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis. Arch Neurol 2005; 62(6): 865–870.

29.

Nakano

Matsui

Inoue

et al . Free immunoglobulin light chain: Its biology and implications in diseases. Clin Chim Acta 2011; 412(11–12): 843–849.

30.

Joseph

Hirst

Pickersgill

et al . CSF oligoclonal band status informs prognosis in multiple sclerosis: A case control study of 100 patients. J Neurol Neurosurg Psychiatry 2009; 80(3): 292–296.

31.

Annunziata

Giorgio

De Santi

et al . Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-β. J Neurol Sci 2006; 244(1–2): 97–102.

32.

Dispenzieri

Kyle

Merlini

et al . International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23: 215–224.

33.

Han

Wang

Zhang

et al . The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphoma. Leuk Res 2014; 38(11): 1291–1298.

34.

Rudick

Medendorp

Namey

et al . Multiple sclerosis progression in a natural history study: Predictive value of cerebrospinal fluid free kappa light chains. Mult Scler 1995; 1: 150–155.

35.

Rinker

Trinkaus

Cross

. Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis. Neurology 2006; 67(7): 1288–1290.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.32 MB

Prognostic value of free light chains lambda and kappa in early multiple sclerosis

Abstract

Background:

Objective:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material